Breakthrough discovery in cancer therapy
Sartar Therapeutics was established to advance a breakthrough discovery in cancer therapy. Using gene expression profiling, we found exceptionally high phosphodiesterase 3A (PDE3A) gene expression in gastrointestinal stromal tumor (GIST), other soft tissue sarcoma subtypes and subsets of other cancers. Our discovery of a novel cancer target, PDE3A, represents a significant leap in cancer therapy.
Innovative precision treatment
We are developing SAR003, a first-in-class breakthrough targeted therapy for cancers expressing the PDE3A gene. Our first indication is gastrointestinal stromal tumour (GIST), a cancer where all tumors express the PDE3A gene.
We have strong IP, patent protection and Orphan Drug Designations (ODD) from EMA and FDA for the treatment of GIST using SAR003.
SAR003 functions as a molecular glue to induce cancer cell death in rapidly dividing cancer cells. Our preclinical proof-of-concept data from sophisticated in vivo models shows outstanding efficacy.
Read more
Sartar Team
Sartar is a company dedicated to the development of targeted therapies for hard-to-treat cancers. Our experienced team is supported by key leading clinical opinion leaders in Europe and US, and a world class vendor network.
Read moreNews
Satu Koskimies has started as a Project Manager
Sartar’s year starts with fantastic recruitment news, as we have welcomed the highly experienced Satu Koskimies to our team! The upcoming year at Sartar means the manufacturing of our investigational drug and the preparations of a clinical trial. Satu works as a project manager, participating in the promotion and development of both of these key […]
Read article
Kiitos kuluneesta vuodesta
Sartarin tiimi haluaa toivottaa kaikille ihanaa joulunaikaa ja onnistumisia uudelle vuodelle! Mikä vuosi meillä onkaan takana! Saimme viimeisteltyä prekliiniset testaukset, FDA:lta harvinaislääkestatuksen kaikkiin pehmytkudossarkoomiin, varmistettua rahoituksen siirtyä kliinisiin tutkimuksiin sekä rekrytoitua huippuosaajia varmistamaan lääkkeemme kehityksen etenemisen. Haluamme kiittää kaikkia Teitä, jotka olette olleet mukana matkallamme tähän asti ja valmiita jatkamaan kanssamme kohti uusia seikkailuja ja […]
Read article
Charlotta Backman started as Sartar’s Head of Clinical Development
Great news for the beginning of December! Sartar has appointed Charlotta Backman as Head of Clinical Development, effective December 1st. Charlotta’s long and diverse experience in designing and conducting clinical trials brings strong expertise to the Sartar team, ensuring that the company progresses in its clinical development as planned. “It is really great to be […]
Read article